FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Medical Devices

Guide on PTA and Specialty Catheter 510(k)s

FDA releases a draft guidance on Peripheral Percutaneous Transluminal Angioplasty (PTA) and Specialty Catheters Premarket Notification (510(k)) Submi...

Human Drugs

SCA Pharma 6-item Form 483 After Inspection

FDA issues SCA Pharmaceuticals a six-observation Form 483 after a November inspection cited GMP issues at the drug outsourcing facility.

Medical Devices

Bayer Removes from Market 99% of Essure Devices

A year after Bayer stopped selling and distributing its Essure implantable contraceptive device, CDRH director Jeff Shuren says Bayer has repossessed ...

Human Drugs

Companies Recall Ranitidine, Nizatidine

FDA says Appco and Northwind have recalled ranitidine and Mylan has recalled nizatidine due to potential NDMA contamination.

Human Drugs

Regeneron Sees Encouraging Garetosmab Results in FOP

Regeneron reports positive results from the LUMINA-1 trial of its garetosmab in treating fibrodysplasia ossificans progressiva.

FDA General

FDA MyStudies Platform on Google Cloud

Health IT News reports that Google is making the FDA MyStudies open-source platform available on Google Cloud.

Human Drugs

Blueprint Medicines GIST Drug Approved

FDA approves a Blueprint Medicines NDA for Ayvakit (avapritinib) for treating certain adults with unresectable or metastatic gastrointestinal stromal ...

Federal Register

FDA Withdrawing 249 ANDAs Over Annual Reports

Federal Register notice: FDA proposes to withdraw approval of 249 ANDAs from multiple companies because they have repeatedly failed to file required a...

Federal Register

Info Collection on Tissue Transplantation

Federal Register notice: FDA submits to OMB an information collection extension for Human Tissue Intended for Transplantation 21 CFR Part 1270.

Human Drugs

Ways to Overcome Drug Company Regulatory System Abuse

Researchers suggest ways Congress could clamp down on abuses of FDA regulatory processes that drug companies use to delay generic competition.